51
|
Francis GS, Greenberg BH, Hsu DT, Jaski BE, Jessup M, LeWinter MM, Pagani FD, Piña IL, Semigran MJ, Walsh MN, Wiener DH, Yancy CW. ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant. J Am Coll Cardiol 2010; 56:424-53. [DOI: 10.1016/j.jacc.2010.04.014] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
52
|
Lockard K, Weimer A, O'Shea G, Driggers E, Conroy L, Teuteberg J, Winowich S, Lohmann D, Schaub R, Severyn D, Kormos R. The Joint Commission's disease-specific care certification for destination therapy ventricular assist devices. Prog Transplant 2010. [DOI: 10.7182/prtr.20.2.k52764070580v516] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
53
|
Lockard KL, Weimer A, O'Shea G, Driggers E, Conroy L, Teuteberg JJ, Winowich S, Lohmann D, Schaub RD, Severyn DA, Kormos RL. The Joint Commission's Disease-Specific Care Certification for Destination Therapy Ventricular Assist Devices. Prog Transplant 2010; 20:155-62. [DOI: 10.1177/152692481002000210] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The Centers for Medicare and Medicaid Services announced that all hospitals implanting ventricular assist devices are required to have certification from the The Joint Commission for disease-specific care destination therapy with a ventricular assist device effective March 27, 2009, in order to receive Medicare reimbursement for services rendered to patients who have devices implanted for destination therapy. On February 23, 2007, The Joint Commission released the certification requirements for ventricular assist devices implanted for destination therapy in an 8-page document so that hospitals could prepare to meet the 2009 certification deadline. The Artificial Heart Program of the University of Pittsburgh Medical Center undertook a multidisciplinary project, under the guidance of the nurse coordinator, to prepare the hospital and program for a precertification survey by The Joint Commission for disease-specific destination therapy ventricular assist device certification. The Presbyterian Hospital Artificial Heart Program was awarded The Joint Commission's device-specific certification for destination therapy with ventricular assist devices in June 2008.
Collapse
Affiliation(s)
- Kathleen L. Lockard
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Ashley Weimer
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Genevieve O'Shea
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Erin Driggers
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Linda Conroy
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Jeffrey J. Teuteberg
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Stephen Winowich
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Douglas Lohmann
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Richard D. Schaub
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Donald A. Severyn
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| | - Robert L. Kormos
- University of Pittsburgh Medical Center, Artificial Heart Program, Pittsburgh, Pennsylvania
| |
Collapse
|
54
|
Abstract
Driveline exit site (DLES) infection is a persistent problem among the left ventricular assist device (LVAD) patients. This study investigated the relationship between obesity and DLES infection. Records of LVAD patients at two institutions from January 1999 to January 2009 were queried. Results were analyzed using t tests. Those with LVAD support > or =90 days were included. The body mass index (BMI) of each patient was measured at the time of implant and at the conclusion of LVAD support or currently, if the patient was ongoing. Other data included preimplant age, ejection fraction, blood urea nitrogen, creatinine, diabetes, New York Heart Association class, pulmonary capillary wedge pressure, VO2 max, and inotrope therapy. The 118 patients who qualified for the study were placed in an infection group (n = 36) or in the control group (n = 82). Both groups had similar preimplant characteristics. Variables with differences statistically significant between the groups included duration of LVAD support, indication for support, device type, and BMI. Patients who developed DLES infections had a significantly higher BMI and continued weight gain over the course of LVAD therapy compared with the control group. Although this association requires further study, implications for clinical practice may include the provision of nutrition and exercise counseling for patients undergoing LVAD therapy, especially if overweight. These results may warrant increased measures to prevent and treat infection in the preimplant and postimplant periods.
Collapse
|
55
|
Slaughter MS, Pagani FD, Rogers JG, Miller LW, Sun B, Russell SD, Starling RC, Chen L, Boyle AJ, Chillcott S, Adamson RM, Blood MS, Camacho MT, Idrissi KA, Petty M, Sobieski M, Wright S, Myers TJ, Farrar DJ. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J Heart Lung Transplant 2010; 29:S1-39. [PMID: 20181499 DOI: 10.1016/j.healun.2010.01.011] [Citation(s) in RCA: 631] [Impact Index Per Article: 45.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2010] [Accepted: 01/17/2010] [Indexed: 02/06/2023] Open
Abstract
Continuous-flow left ventricular assist devices (LVAD) have emerged as the standard of care for advanced heart failure patients requiring long-term mechanical circulatory support. Evidence-based clinical management of LVAD-supported patients is becoming increasingly important for optimizing outcomes. In this state-of-art review, we propose key elements in managing patients supported with the new continuous-flow LVADs. Although most of the presented information is largely based on investigator experience during the 1,300-patient HeartMate II clinical trial, many of the discussed principles can be applied to other emerging devices as well. Patient selection, pre-operative preparation, and the timing of LVAD implant are some of the most important elements critical to successful circulatory support and are principles universal to all devices. In addition, proper nutrition management and avoidance of infectious complications can significantly affect morbidity and mortality during LVAD support. Optimizing intraoperative and peri-operative care, and the monitoring and treatment of other organ system dysfunction as it relates to LVAD support, are discussed. A multidisciplinary heart failure team must be organized and charged with providing comprehensive care from initial referral until support is terminated. Preparing for hospital discharge requires detailed education for the patient and family or friends, with provisions for emergencies and routine care. Implantation techniques, troubleshooting device problems, and algorithms for outpatient management, including the diagnosis and treatment of related problems associated with the HeartMate II, are discussed as an example of a specific continuous-flow LVAD. Ongoing trials with other continuous-flow devices may produce additional information in the future for improving clinical management of patients with these devices.
Collapse
|
56
|
Vrtovec B, Radovancevic R, Delgado RM, Radovancevic B, Bracey AW, Gregoric ID, Frazier OH. Significance of anaemia in patients with advanced heart failure receiving long-term mechanical circulatory support. Eur J Heart Fail 2010; 11:1000-4. [PMID: 19789404 DOI: 10.1093/eurjhf/hfp110] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
AIMS The aim of this study was to analyse the prognostic impact of anaemia in patients receiving long-term left ventricular assist device (LVAD) support. METHODS AND RESULTS We reviewed the data of 65 consecutive patients who underwent LVAD support for at least 6 months. Anaemia was defined as haemoglobin levels <12.0 g/dL. Follow-up was performed 15 months after implantation. Anaemia was present in 30/65 patients (46%) after 6 months of LVAD support. Anaemic patients had higher levels of pre-implant creatinine (1.8 +/- 0.8 vs. 1.4 +/- 0.5 mg/dL; P = 0.04). The presence of anaemia after 6 months correlated with higher levels of creatinine and blood urea nitrogen and lower levels of albumin. Multivariate Cox proportional hazards regression analysis revealed that levels of haemoglobin <12 g/dL [risk ratio (RR), 8.94; 95% confidence interval (CI), 1.09-73.01; P = 0.04], creatinine >1.4 mg/dL (RR, 5.39; 95% CI, 1.78-16.30; P = 0.003), and albumin <1.5 g/L (RR, 3.23; 95% CI, 1.10-9.51; P = 0.03) were associated with all-cause mortality at 15 months. Long-term survival evaluated by Kaplan-Meier analysis was two times higher in non-anaemic patients after 6 months of LVAD support than in anaemic patients (P = 0.01). CONCLUSION Anaemia is related to adverse outcomes in patients receiving prolonged LVAD support.
Collapse
Affiliation(s)
- Bojan Vrtovec
- Center for Cardiac Support, Texas Heart Institute at St Luke's Episcopal Hospital, Houston, TX 77225-0345, USA
| | | | | | | | | | | | | |
Collapse
|
57
|
Wilson SR, Givertz MM, Stewart GC, Mudge GH. Ventricular Assist Devices. J Am Coll Cardiol 2009; 54:1647-59. [DOI: 10.1016/j.jacc.2009.06.035] [Citation(s) in RCA: 119] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2009] [Revised: 06/18/2009] [Accepted: 06/21/2009] [Indexed: 11/15/2022]
|
58
|
|
59
|
Campos Rubio V. Criterios hemodinámicos y funcionales de indicación de una asistencia en la insuficiencia cardíaca aguda (shock cardiogénico). CIRUGIA CARDIOVASCULAR 2009. [DOI: 10.1016/s1134-0096(09)70153-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
60
|
Abstract
Heart failure affects more than 5 million people in the United States. The treatments of this disease include medical therapy, heart transplantation, and the implantation of ventricular assist devices. These devices are used in patients who are no longer responsive to conservative medical treatment, who are not candidates for a heart transplantation (destination therapy), who are awaiting a heart transplantation (bridge to transplantation), and who have acute heart failure and whose myocardial function is expected to return to normal (bridge to recovery). Although this therapy improves the mortality and quality of life among patients with heart failure, the devices also carry risk of multiple complications. This article discusses the acute and long-term complications of ventricular assist devices.
Collapse
|
61
|
Postcardiotomy Cardiogenic Shock: The Role of Ventricular Assist Devices. Crit Care Nurs Clin North Am 2007; 19:427-43, vi-vii. [DOI: 10.1016/j.ccell.2007.07.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
62
|
Stahovich M, Chillcott S, Dembitsky WP. The next treatment option: using ventricular assist devices for heart failure. Crit Care Nurs Q 2007; 30:337-46. [PMID: 17873570 DOI: 10.1097/01.cnq.0000290367.54998.29] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Ventricular assist devices (VADs) are becoming more commonplace in the hospital and community settings as the number of patients living with heart failure increases. Patients being discharged after hospitalization for heart failure rose from 399 000 in 1979 to 1 099 000 in 2004, an increase of 175%. Patients with heart failure become severely debilitated finding activities of daily living including eating, bathing, and walking a great effort. Patients with end-stage heart failure are often sent home on inotropic therapies and referred to hospice care. The use of VADs for these patients can dramatically improve both the quality and the length of life. VADs can be broadly categorized as being either continuous flow (fluid dynamic) or pulsatile (volume displacement) and either can be used as short- or long-term support devices. The critical care nurse is in a unique position to educate patients with chronic heart failure on options available to improve their quality of life including VAD therapy. VADs are available for destination therapy for those not meeting transplant criteria, offering a longer quality of life. As centers gain more experience and referrals are made earlier in the disease process, VAD patient care will be more streamlined decreasing length of stay.
Collapse
|
63
|
Carberry KE, Gunter KS, Gemmato CJ, Morales DLS. Mechanical circulatory support for the pediatric patient. Crit Care Nurs Q 2007; 30:121-42. [PMID: 17356354 DOI: 10.1097/01.cnq.0000264256.98122.9c] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In adult patients, mechanical circulatory support (MCS) devices are part of the standard of care for heart failure. There are several options available that clinicians may use to provide support for their patients and thus the choice of devices can be tailored to their individual needs. Unfortunately, this is not the case for pediatric patients with heart failure, where the options for MCS modalities are far more limited because of size constraints and regulatory hurdles. Furthermore, the pathophysiology of heart failure in children is not identical to that of adults; thus, the device selection and configuration require different considerations. Management of pediatric patients on MCS requires a highly specialized team of pediatric professionals. The nurse caring for a child on MCS is an active participant in all aspects of the patient's care and must have an in-depth understanding of the patient's underlying physiology, the circulatory physiology of the MCS system, the reason for mechanical support, and the goal of support.
Collapse
Affiliation(s)
- Kathleen E Carberry
- Center for Clinical and Outcomes Research, Congenital Heart Surgery Service, Texas Children's Hospital, Houston, Texas 77030, USA.
| | | | | | | |
Collapse
|
64
|
Miller LW, Lietz K. Candidate Selection for Long-term Left Ventricular Assist Device Therapy for Refractory Heart Failure. J Heart Lung Transplant 2006; 25:756-64. [PMID: 16818117 DOI: 10.1016/j.healun.2006.03.007] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2005] [Revised: 02/28/2006] [Accepted: 03/13/2006] [Indexed: 10/24/2022] Open
Affiliation(s)
- Leslie W Miller
- Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota 55455, USA.
| | | |
Collapse
|
65
|
Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. THE LANCET. INFECTIOUS DISEASES 2006; 6:426-37. [PMID: 16790383 DOI: 10.1016/s1473-3099(06)70522-9] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Heart failure is a leading cause of death in developed nations despite medical management. Cardiac transplantation is a potentially lifesaving intervention for approximately 4000 advanced heart failure patients per year; however, the demand for donor hearts far exceeds the supply. Ventricular assist devices provide temporary support for patients with severe heart failure until myocardial recovery occurs or a donor heart becomes available. For those ineligible for transplantation, ventricular assist devices may be used permanently and have demonstrated reduced mortality and an improved quality of life compared with continued medical therapy. Nonetheless, these devices are under-used, in part due to the frequency of complications. Device-related infections are one of the most frequent sequelae of ventricular assist device placement and occur in 18-59% of cases. Infections can involve any part of the device and confer substantial morbidity and mortality. Here, we provide an introduction to ventricular assist devices, explore the nature and pathogenesis of ventricular assist device-related infections, discuss problems with diagnosis, and present treatment and prevention strategies.
Collapse
Affiliation(s)
- Rachel J Gordon
- Division of Infectious Diseases, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
| | | | | |
Collapse
|